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The present work describes development and validation of a specific, sensitive, precise and stability-
indicating high-performance liquid chromatographic method of analysis of atorvastatin calcium and 
celecoxib, both as a bulk drug and in niosomal formulation. The analysis has been performed by using 
Cosmosil-C18 column (4.6 mm×250 mm, 5 µ) at 25 °C using acetonitrile: ammonium acetate buffer 
pH 5.0: methanol (50:25:25 v/v/v) as mobile phase. The detection was carried out at 277nm with a flow 
rate of 1.0mL/min. The retention times of Atorvastatin calcium and Celecoxib were 6.195 and 3.989min, 
respectively. The method was validated according to ICH guidelines, for specificity, precision, linearity, 
accuracy and robustness. Atorvastatin calcium and Celecoxib were subjected to stress conditions of 
hydrolysis, oxidation, photolysis and thermal degradation. The degradation was observed in oxidation 
and acid hydrolysis. The linearity for atorvastatin calcium and celecoxib were in the range of 100-500 
µg/mL. The recovery study of atorvastatin and celecoxib were found to be in the range of 98.96 – 
99.92% and 98.90–100%, respectively. The proposed method was validated and successfully applied 
to the estimation of Atorvastatin calcium and Celecoxib in combined in-house niosomal formulation.
Uniterms: Atorvastatin calcium/determination. Celecoxib/determination. High performance liquid 
chromatography/quality control. Niosomal formulation/quality control. Pharmaceutical formulations/
quality control.
O presente trabalho descreve o desenvolvimento e a validação de método de análise por cromatografia 
de alta eficiência específico, sensível, preciso e indicador de estabilidade de atorvastatina cálcica e 
celecoxibe, ambos como fármaco e como formulação niosômica. A análise foi realizada utilizando coluna 
Cosmosil-C18 (4,6 mm×250 mm, 5 µ) a 25 °C, e acetonitrila: tampão acetato de amônio pH 5,0: metanol 
(50:25:25 v/v/v) como fase móvel. A detecção foi realizada a 277 nm, com fluxo de 1,0 mL/min. Os 
tempos de retenção de atorvastatina cálcica e de celecoxibe foram 6,195 e 3,989 min, respectivamente. O 
método foi validado de acordo com as regras da ICH para especificidade, precisão, exatidão e robustez. 
A atorvastatina cálcica e o celecoxibe foram submetidos a condições de estresse por hidrólise, oxidação, 
fotólise e degradação térmica. A degradação foi observada por oxidação e hidrólise ácida. Observou-se 
a linearidade da atorvastatina cálcica e do celecoxibe na faixa de 100-500 µg/mL. A recuperação da 
atorvastatina e do celecoxibe foi observada na faixa de 98,96-99,92% e 98,90-100%, respectivamente. 
O método proposto foi validado e aplicado com sucesso para a determinação de atorvastatina cálcica e 
celecoxibe em formulação niosômica caseira combinada. 
Unitermos: Atorvastatina cálcica/determinação. Celecoxibe/determinação. Cromatografia líquida de 
alta eficiência/controle de qualidade Formulação de niosomal/controle de qualidade. Formulações 
farmacêuticas/controle de qualidade.
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INTRODUCTION
Atorvastatin calcium is [R-(R*,R*)]-2-(4-
fluorophenyl)-ß,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-
4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic 
acid, calcium salt (2:1) trihydrate [Figure1(a)] (IP, 2007). 
Atorvastatin is a selective, competitive inhibitor of HMG-
CoA reductase, the rate-limiting enzyme that converts 
3-hydroxy-3-methylglutaryl-coenzyme A to mevalonate, 
a precursor of sterols, including cholesterol. Atorvastatin 
lowers plasma cholesterol and lipoprotein levels by 
inhibiting HMG-CoA reductase and cholesterol synthesis 
in the liver and by increasing the number of hepatic LDL 
receptors; Atorvastatin also reduces LDL production and 
the number of LDL particles (Narwal, et al., 2010; Moffat, 
c2004).
C e l e c o x i b  i s  p - [ 5 - p - m e t h y l p h e n y l - 3 -
(trifluoromethyl)-1H-pyrazol-1-yl]benzene sulfonamide 
[Figure 1(b)]  (Moffat ,  c2004),  i t  is  a  selective 
cycloxygenase-2 (PTGS2/ COX2) inhibitor used for 
treatment of osteoarthritis and rheumatoid arthritis. 
It acts by reducing prostaglandin synthesis through 
inhibition of COX-2. Selective COX-2 inhibitors appear 
to provide comparable anti-inflammatory effects to 
conventional non-steroidal anti-inflammatory agents 
(NSAIDs), while avoiding serious adverse reactions, 
in particular, gastrointestinal toxicity observed with 
chronic use of NSAIDs due to COX-1(PTGS1) inhibition 
(Konstantinopoulos, Lehmann, 2005).
Recent studies have indicated that in addition to 
the cholesterol-lowering effect, statins have pleiotropic 
activities that modulate other biological processes, such 
as cell proliferation and apoptosis. Hence, Atorvastatin 
acts as an anticancer agent. Celecoxib also induces the 
anticancer activity, the mechanism of action being that 
COX-2-derived PGE2 potentiates androgen biosynthesis 
by the cytochrome P450 enzyme aromatase and promotes 
angiogenesis, tumor maintenance/growth, and metastasis. 
The simultaneous inhibition of aromatase and COX-2 
activity may therefore be responsible for the anticancer 
activity of celecoxib. Combinations of low doses of 
these anticancer agents i.e. Atorvastatin and celecoxib 
that have different mechanisms of action may together 
have significantly improved efficacy for inhibiting 
tumor formation and tumor growth when compared with 
individual anticancer substances alone (Xi, Xiao-Xing, 
Gina, 2007). However, both these drugs belongs to BCS 
class II and suffer from bioavalability problem (ATV Ca 
14% and CXB 40%). Niosomes are microscopic lamellar 
structures formed on admixture of a nonionic surfactant, 
cholesterol and chloroform with subsequent hydration 
in aqueous media. They behave in vivo like liposomes 
prolonging the circulation of entrapped drug and altering 
its organ distribution. As drug delivery vesicles, niosomes 
have been shown to enhance absorption of some drugs 
across cell membranes, to localize in targeted organs 
and tissues and to elude the reticuloendothelial system. 
Niosomes can accommodate drug molecules with a 
wide range of solubility and thus can show better anti-
angiogenic activity as compared to drugs as such (Abhinav 
et al., 2011; Keservani et al., 2011).
Literature survey reveals spectroscopic methods for 
determination of ATV as single drug or in combination with 
other drugs (Prajapati, Bhandari, 2011; Dey, et al., 2012). 
In addition, some HPLC, HPTLC and stability indicating 
methods have been reported for estimation of ATV in 
pharmaceutical dosage forms (Surekha, Swamy, Kumar, 
2012; Krishnan et al., 2011; Kumar, Ghosh, Chaudhary, 
2012; Mhaske, et al., 2012). CXB has been determined by 
UV-spectrophotometric, by HPLC and stability indicating 
methods (Revathi, et al., 2011; Jadhav, Gowekar, Gowekar, 
2012; Baboota, et al., 2007). Plasma determination of 
CXB has also been reported (Emami, Fallah, Ajami, 
2008). Various spectrophotometric and HPLC methods 
are reported for determination of atorvastatin and CXB 
alone and in combination with otherdrugs (Ahmed, 
Manohara, Ravi, 2012; Vijayamirtharaj et al., 2010). 
However, no Reverse phase (RP)-HPLC method has been 
reported so far for simultaneous estimation of ATV Ca 
and CXB. The aim of the present work was to develop 
simple, precise, accurate and reproducible RP-HPLC 
method for simultaneous determination of this binary drug 
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FIGURE 1 - Chemical structures of ATV Ca (a) and CXB (b).
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formulation. The proposed method was optimized and 
validated in accordance with International Conference on 
Harmonization (ICH) guidelines (ICH, 2005).
EXPERIMENTAL
Chemicals and reagents
Pure samples of ATV Ca (Batch No. 121704002) 
and CXB (Batch No. 121983002) were provided as a gift 
sample by Lupin Research Park, Pune, India. Niosomes 
prepared by using span 60, cholesterol and cholroform. All 
the chemicals and reagents used were of HPLC grade and 
purchased from Loba chemie Pvt. Ltd., Mumbai, India.
Instrument
The development and validation of the method was 
performed on a Shimadzu (LC 2010 CHT, Kyoto, Japan) 
having quaternary system with automatic injection facility. 
The detector consists of a UV-Vis model and was operated 
at 277 nm. The software used was ‘LC Solution’. The 
column used was Cosmosil C18 column (4.6 mm×250 
mm, 5µ). Shimadzu (UV-1800, Japan) double beam 
spectrophotometer with two identical quartz cells was used 
for absorbance measurement.
Methods
Preparation of In house niosomes
Niosomal Formulation was optimized acc. to 
type of surfactant and method of preparation. The best 
surfactant was found to be span 60 among Span 20, Span 
60, Span 80 and similarly better result were obtained 
with ether injectiom method over Hand shaking and 
sonication methods. Further optimization was done w.r.t 
concentration of span 60. The optimized formulation 
prepared by ether injection method containing Span 
60:cholesterol: drug in 1:1:1(w/w/w) concentation 
(i.e 50 mg Span 60, 50 mg cholesterol, 25 mg ATV 
Ca+25mg CXB) was used for chromatographic 
evaluation.
Chromatographic conditions
Chromatographic separation was achieved at 
250 °C and the detection was carried at 277nm at a flow 
rate of 1mL/min. Run time was kept at 10 min. Prior to 
the injection of drug solution, column was equilibrated 
for 60min with the mobile phase flowing through the 
system. The injection volume was 20 µL for assay level. 
The analysis was performed by using Cosmosil C18 
(4.6 mm×250 mm, packed with 5 µm particle size) and the 
mobile phase consisting of acetonitrile: ammonium acetate 
buffer pH 5.0: methanol (55: 20:25v/v/v).
Standard preparation
The standard stock solutions: 1000 µg/mL of ATV 
Ca and CXB were prepared separately by dissolving 
working standards in methanol and diluting with the same 
solvent. Standard calibration solutions of ATV Ca and 
CXB having concentrations in the range of 100-500 µg/
mL were prepared separately by diluting stock solutions 
with methanol. A representative chromatogram of standard 
preparation is shown in Figure 2.
FIGURE 2 - Chromatogram of standard preparation of ATV Ca and CXB.
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Sample solution
In house niosomal formulation of 50 mLwas 
prepared containing 25 mg ATV Ca and 25 mg CXB in 
combination. Sample of niosomal formulation equivalent 
to 5 mg of ATV Ca and CXB was accurately weighed 
and transferred into 10 mL volumetric flask and then 
diluted with methanol. The contents were sonicated for 
15 minutes with intermittent shaking. This solution was 
filtered through 0.45 µm nylon filter, discarding first three 
mL of filtrate. Representative chromatogram of sample 
preparation is shown in Figure 3.
Analytical method validation
System suitability parameters
Mixed standard solution of ATV Ca and CXB 
was injected into the system for five times and system 
suitability parameters (tailing factor, retention time and 
theoretical plates) were checked.
Specificity
To assess the method specificity, blank and placebo 
solutions were injected into the HPLC system using the 
test conditions as specified above. The chromatogram was 
recorded and the responses of the peaks if any measured.
Linearity
The linearity of method was obtained by preparation 
of the calibration curve in 6 replicates. The calibration 
curve for ATV Ca and CXB was obtained by plotting 
separately the peak area of ATV Ca and CXB versus 
concentration of ATV Ca and CXB over the range of 100-
500 µg/mL.
Accuracy
The recovery experiments were performed by 
adding a known quantity of pure standard drug into the 
solution of the tablet powder. The sample was then spiked 
with standard at levels 80%, 100% and 120% of test 
concentration. The resulting spiked sample solutions were 
assayed in triplicate.
Precision
The precision of an analytical procedure expresses 
the closeness of agreement (degree of scatter) between a 
series of measurements obtained from multiple sampling 
of the same homogeneous sample under the prescribed 
conditions. Repeatability of standard application (System 
precision) and inter day precision study of ATV Ca and 
CXB were carried out by estimating the corresponding 
responses on the same day and on next day for 3 different 
concentrations of ATV Ca and CXB (200, 300, 400 µg/
mL) in triplicate. Repeatability expresses the precision 
under the same operating conditions over a short interval 
of time. Repeatability is also termed intra-assay precision.
Robustness
Robustness of the method was determined by 
analyzing standard solutions at normal operating 
conditions and by changing some operating analytical 
conditions such as flow rate (0.8, 1.0 and 1.2 mL/min), 
mobile phase ratio (52:23:25, 50:25:25 and 48:27:25 
v/v/v), and detection wavelength (275, 277 and 279 nm). 
LOD & LOQ
Six sets of Calibration curve were prepared and LOD 
and LOQ were calculated by using the formula:
FIGURE 3 - Chromatogram of sample preparation of ATV Ca and CXB.
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S
SDLOD 3.3=
S
SDLOQ 10=  
where SD is standard deviation of y-intercept of the 
calibration curves; S is mean slope of six calibration 
curves.
Forced Degradation Studies
ATV Ca and CXB standard samples were degraded 
under different stress conditions like acidic, alkali, 
oxidative hydrolysis and dry heat conditions. For acid and 
base degradation, samples were refluxed with 1M HCl and 
1M NaOH at 70 °C for 3 h. For oxidation, 30% v/v H2O2 
was refluxed at 70 °C for 3 h. For thermal degradation, 
sample was exposed to heat in oven at 100 °C for 6 h and 
for photo degradation; drug was exposed to direct sunlight 
for 6 h. Acid and base treated samples were neutralized 
and all the samples were then diluted to a concentration of 
500 μg/mL with methanol. The samples were withdrawn 
and subjected to RP-HPLC analysis under optimized 
conditions.
RESULTS AND DISCUSSION
Method
For HPLC method optimization, different ratios of 
acetonitrile and ammonium acetate buffer pH5 were tried 
but resolution of peak was not achieved. So, methanol was 
used as third mobile phase. Different ratios of acetonitrile, 
Ammonium acetate buffer pH5 and methanol were tried 
i.e. 60:20:20 v/v/v, 65:15:20 v/v/v, 55:25:20v/v/v. It 
was found that acetonitrile: ammonium acetate buffer: 
methanol in the ratio 50:25:25 v/v/v as mobile phase 
at a flow rate of 1.0 mL/min gave good peaks. Thus, 
Cosmosil-C18 (4.6 mm×250 mm, 5 µm) column, 1 mL/
min flow rate, 20 µL injection volume, 25 °C column oven 
temperature, 277 nm wavelength were the conditions, 
which were found to be suitable for the separation of 
peaks. These chromatographic conditions gave a retention 
time of 6.195 and 3.989 min for ATV Ca and CXB, 
respectively.
System suitability parameters
System suitability parameters (tailing factor, 
retention time and theoretical plates) were found within 
acceptance criteria. Relative standard deviation (RSD) for 
area was found satisfactory and meeting ICH specifications 
(% RSD≤2%). Summary of system suitability parameters 
is tabulated in Table I.
Specificity
Specificity of the method was checked by injecting 
the placebo solution; no peaks were found at the retention 
time of ATV Ca and CXB.
Linearity
A good linear relationship as indicated by correlation 
coefficient value 0.997 and 0.999 were observed for 
ATV Ca and CXB, respectively over the range of 100-
500µg/mL. The slope and intercept value for calibration 
curve was found as; y=16398x+18575 for ATV Ca and 
y=9235x+30017 for CXB. The results of linearity are 
tabulated in Table II.
Accuracy
The accuracy of the method was determined 
by recovery studies and the percentage recovery was 
calculated. The recoveries of ATV Ca and CXB were found 
to be in the range of 98.96 - 99.92% and 98.90 - 100%, 
respectively. The results were compared with the expected 
results and expressed as percentage as given in Table III.
Precision
The precision of the method is satisfactory as % RSD 
is not more than 2%. The results of the precision study are 
given in Table IV.
TABLE I - Summary of system suitability parameters 
S y s t e m  s u i t a b i l i t y 
parameter
Observations Acceptance criteria
ATV Ca CXB
Tailing factor 1.209 1.089 ≤ 2
Retention Time (tR) (min) 6.195 3.989 ≥ 2
Theoretical plates 4484.450 2729.27 ≥ 2000
% RSD* of area 0.144 0.356 ≤ 2
* n=5
TABLE II - Results of linearity
Parameter ATV Ca CXB
Linearity range 
(µg/mL)
100-500 100-500
r2 ± SD* 0.997 ± 0.0005 0.999 ± 0.0057
Slope ± SD* 16206 ± 23.51 9099.8 ± 26.52
Intercept± SD* 360880 ± 5643.49 45259.33 ± 2738.38
LOD (µg/mL) 1.149176 0.993063
LOQ (µg/mL) 3.482351 3.009282
*n=6
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Robustness
The results for robustness of the method are given in 
Table V; the results obtained were satisfactory as % RSD 
found to be less than 2%. The parameters like tailing factor 
and retention times showed adherence to the limits.
LOD and LOQ
Results of LOD and LOQ are tabulated in Table II.
Analysis of In-house niosomal formulation
The proposed liquid chromatographic method 
was applied to the determination of ATV Ca and CXB 
in their combined dosage forms (In-house prepared 
niosomal formulation). The results for ATV Ca and CXB 
were comparable with the corresponding added/labeled 
amounts given in Table VI.
Forced degradation study
The drugs were degraded under acidic and oxidative 
condition while they were stable in alkaline, photolytic and 
thermal conditions. The ATV Ca gets degraded to form the 
lactone compound while the degradation product of CXB is 
unknown (Shah, Kumar, Singh, 2008). The chromatogram 
of forced degradation studies is given in Figure 5 and the 
results of stability studies are given in Table VII.
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FIGURE 4 - (a) Linearity of CXB ; (b) Linearity of ATV Ca.
TABLE III - Results of Accuracy study
Drug Level Theoretical Amount (µg/
mL)
Mean % Recovery % RSD*
ATV Ca
50% 150 98.75 0.34
100% 300 98.25 0.39
150% 450 99.81 0.57
CXB
50% 150 99.44 0.45
100% 300 97.56 0.81
150% 450 99.65 0.74
*n=3
TABLE IV - Results of precision study
Drug Concentration (µg/mL) Inter-day (%RSD*) Repeatability (%RSD*)
ATV Ca
200 0.125 0.132
300 0.178 0.183
400 0.171 0.179
CXB
200 0.07 0.05
300 0.04 0.08
400 0.04 0.05
*n=3
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TABLE V - Results of robustness studies
Robustness study of ATV Ca
Chromatographic changes
Robustness study of CXB
Chromatographic changes
Factor Level
Retention time 
(tR) (min)
Area Factor Level Retention time (tR) (min)
Area
Flow rate (mL/min) Flow rate (mL/min)
0.8 -0.2 6.172 13044484 0.8 -0.2 3.995 7350366
1.0 0 6.12 12666143 1.0 0 3.985 7196852
1.2 0.2 6.173 12933150 1.2 0.2 3.993 7255729
%RSD* 0.4925 1.5094 %RSD* 0.1325 1.0656
Ratio of Mobile phase 
(ACN: Ammonium acetate buffer pH 5.0: Methanol)
Ratio of Mobile phase 
(ACN: Ammonium acetate buffer pH 5.0: Methanol)
52:23:25 -2 6.119 12670019 52:23:25 -2 3.982 7196852
50:25:25 0 6.12 12666143 50:25:25 0 3.985 7196852
48:27:25 2 6.166 12924476 48:27:25 2 3.994 7330361
%RSD* 0.4376 1.1607 %RSD* 0.1566 1.0644
Wavelength (nm) Wavelength (nm)
275 -2 6.08 12449856 275 -2 3.961 7217802
277 0 6.12 12666143 277 0 3.985 7196852
279 2 6.104 12758710 279 2 3.98 6983030
%RSD* 0.3299 1.2554 %RSD* 0.3185 1.8215
* n=3
TABLE VI - Result of analysis of In-house niosomal formulation 
by proposed RP-HPLC method
Parameters ATV Ca CXB
Label Claim (mg) 25 25
Actual content found* (mg) 24.78±0.78 24.82±0.08
% Recovery 99.12 99.28 
% RSD*  0.53% 0.8%
*n=3
TABLE VII - Degradation studies of ATV Ca and CXB by HPLC
Stress condition Amount of ATV Ca 
degraded (%)
Amount of ATV Ca 
recovered (%)
Amount of CXB 
degraded (%)
Amount of CXB 
recovered (%)
tR of degraded 
products (min)
1 M HCl (3 h at 70 °C) 11.19 88.80 4.29 95.70 4.933
1 M NaOH (3 h at 70 °C) 0.039 99.96 0.12 99.87 -
H2O2 (3 h at 70 °C) 28.81 71.18 14.89 85.10 1.156, 8.376
Dry heat (6 h at 100 °C) 2.52 97.47 0.076 99.92 -
Sunlight(6 h) 2.18 97.81 0.094 99.90 -
tR= Retention time, - = no degradation
CONCLUSIONS
The HPLC method developed for the analysis of 
mixture of ATV Ca and CXB in their pharmaceutical 
preparations is stability indicating, precise, accurate and 
with a short run time. The method was fully validated 
showing satisfactory data for all the method validation 
parameters tested. The developed method can be 
conveniently applied for the routine estimation of ATV 
Ca and CXB.
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